Guidelines Are Urgently Needed for the Use of Preprints as a Source of Information

Kazuki Ide1,2, Hitoshi Koshiba3, Philip Hawke4, and Misao Fujita1,5

1Uehiro Research Division for iPS Cell Ethics, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
2The Institute of Natural Sciences, College of Humanities and Sciences, Nihon University, Tokyo, Japan
3National Institute of Science and Technology Policy, Tokyo, Japan
4School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
5Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan

Received October 21, 2020; accepted October 27, 2020; released online November 7, 2020

In response to the recent COVID-19 pandemic, preprints of articles on this disease have been uploaded to preprint servers at a remarkable rate. While preprints can certainly serve as a useful source of preliminary information, this information has yet to be peer reviewed, and is therefore at greater risk of error and unreliability. Retraction Watch reports that eleven articles on COVID-19 had been withdrawn from preprint servers up to October 2, 2020.1 In this letter, we use quantitative data to examine in greater detail the issue of preprint withdrawal and the risk of using preprints as a source of information. We also suggest guidelines for avoiding this risk.

The increasing popularity of preprint servers clearly demonstrates that making scientific information that has not yet undergone peer review publicly available can be valuable in facilitating the timely discussion of preliminary results. However, errors in this information can not only lead to complications for scientists citing it in their research, but can also cause confusion among medical professionals and government officials using it to manage the emerging pandemic.2 For example, an article in The Lancet Infectious Disease by Verity et al cited a preprint article posted to the medRxiv server by Yang et al which focused on the epidemiological and clinical situation related to COVID-19 in China.3,4 This preprint paper was later withdrawn, however, forcing Verity et al to announce a correction to their own paper. Yang et al stated in a withdrawal letter that the “methods and the main conclusions in our original analyses remain solid” and that they “will replace it with a more up-to-date version shortly.” However, no such updated version had appeared on medRxiv over eight months later. Significantly, the Yang et al preprint was also cited in a report on COVID-19 published by Imperial College London that was aimed at a general readership and which received substantial media coverage.4 Cases such as this reveal that the current handling of preprints is causing confusion and perhaps even misinformation.

To better understand the problems surrounding preprints, we compiled a database of postings to six major preprint servers over time (arXiv, ChemRxiv, medRxiv, bioRxiv, Social Science Research Network (SSRN), and Preprints with The Lancet), as visualized in Figure 1. We found that 16,066 articles had been posted as of the end of September 2020.

We then searched this database for withdrawals. On medRxiv, the most frequently used preprint server for medical research, six preprints had been withdrawn. Although a notice of withdrawal was clearly stated on the web page for each paper, the reason given for the withdrawal was in the majority of cases quite vague, such as “The authors have withdrawn their manuscript whilst they perform additional experiments to test some of their conclusions further.” To the server’s credit, the previous versions of the papers were still available on the web page for each article. Nevertheless, the PDFs of these previous versions did not have withdrawal notices printed directly on them, an oversight which could easily lead to confusion when copies of the PDF are downloaded. Of greater concern, two studies on the use of ivermectin against COVID-19 posted on SSRN had been withdrawn, and both the papers themselves and the web pages recording their posting history had completely disappeared from the server. No explanation for the withdrawals could be found. The deletion of these papers may be particularly significant as ivermectin has received considerable attention as a potential treatment. These findings also point to the difficulty of using preprints as a source of information.

Several factors contribute to this difficulty. The screening process for posting on preprint servers takes only a few days (2 days for bioRxiv, 4–5 days for medRxiv).5 This is much shorter than even the average 60 days required by the new rapid peer review policies instituted by many journals in response to the recent surge in COVID-19-related articles.5 In addition, depending on the server, changes in the status of a preprint may not be made clear. In the case of retracted peer-reviewed articles, the standard policy is for the publisher to keep the article in its original location with a retraction notice attached to it. However, in the case of withdrawn preprints, the policy depends on the server. Some servers allow preprints to be simply removed, preventing any follow up of information they contain that has been cited or used for other purposes. Even when a withdrawn paper does remain archived on its web page with a withdrawal

Address for correspondence. Kazuki Ide, Uehiro Research Division for iPS Cell Ethics, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan (e-mail: ide.kazuki.2r@kyoto-u.ac.jp, ide.kazuki.2r@kyoto-u.jp).
Guidelines Are Needed for the Use of Preprints

Figure 1. Preprint article publications on COVID-19 over time. Cumulative graph showing the number of preprint articles about COVID-19 published on six preprint servers (arXiv, ChemRxiv, medRxiv, bioRxiv, Social Science Research Network (SSRN), and Preprints with The Lancet).

Ethical Approval

As this commentary is based exclusively on publicly available data that contains no personal information, ethical approval is not required.

Acknowledgments

This study was supported by the Uehiro Foundation on Ethics and Education (KI and MF), by a research grant from the Watanabe Memorial Foundation for the Advancement of New Technology (R2-524 to KI), and by a Grant-in-Aid for Early-Career Scientists from the Japan Society for the Promotion of Science (18K13110 to KI).

Conflicts of interest: None declared.

References

1. Retraction Watch. Retracted coronavirus (COVID-19) papers. https://retractionwatch.com/retracted-coronavirus-covid-19-papers/. Accessed October 2, 2020.
2. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669–677.
3. Yang Y, Lu Q, Liu M, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. doi: https://
4. Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand [Imperial College London report on COVID-19]. https://bit.ly/3cQOVw6. Accessed October 2, 2020.

5. Kwon D. How swamped preprint servers are blocking bad coronavirus research. Nature. 2020;581:130–131.

6. Committee on Publication Ethics (COPE). Discussion document on preprints. doi: https://doi.org/10.24318/R4WBya02.